Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
Author:
Affiliation:
1. Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center Nashville Tennessee USA
Publisher
Wiley
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.338
Reference31 articles.
1. Axicabtagene ciloleucel: the first FDA‐approved CAR T‐cell therapy for relapsed/refractory large B‐cell lymphoma;King AC;J Adv Pract Oncol,2019
2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
4. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
5. Outcomes in ZUMA‐5 with axicabtagene ciloleucel (axi‐cel) in patients (pts) with relapsed/refractory (R/R) indolent non‐Hodgkin lymphoma (iNHL) who had the high‐risk feature of progression within 24 months from initiation of first anti‐CD20–containing chemoimmunotherapy (POD24);Jacobson CA;J Clin Ancol,2021
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Therapeutic approaches of cell therapy based on stem cells and terminally differentiated cells: Potential and effectiveness;Cells & Development;2024-02
2. Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”;International Journal of Molecular Sciences;2023-12-10
3. Is the Central Nervous System Reservoir a Hurdle for an HIV Cure?;Viruses;2023-12-05
4. Information-Theoretic Analysis of a Model of CAR-4-1BB-Mediated NFκB Activation;Bulletin of Mathematical Biology;2023-12-01
5. Universal ddPCR-based assay for the determination of lentivirus infectious titer and lenti-modified cell vector copy number;Molecular Therapy - Methods & Clinical Development;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3